Grifols, S.A. (GRF.MC)
| Previous close | 18.61 |
| Open | 18.80 |
| Bid | 18.52 x 0 |
| Ask | 18.53 x 0 |
| Day's range | 18.45 - 19.04 |
| 52-week range | 14.10 - 23.42 |
| Volume | |
| Avg. volume | 1,155,087 |
| Market cap | 10.855B |
| Beta (5Y monthly) | 0.18 |
| PE ratio (TTM) | 19.12 |
| EPS (TTM) | 0.97 |
| Earnings date | 24 Feb 2022 - 28 Feb 2022 |
| Forward dividend & yield | 0.36 (1.85%) |
| Ex-dividend date | 03 Jun 2021 |
| 1y target est | 22.86 |
- Motley Fool
Got $20? These 3 Healthcare Stocks Could Be Bargain Buys for 2022 and Beyond
On top of those pluses, these three companies all have a history of offering above-average dividends, making them solid long-term value bargains. Takeda is a Japanese biopharmaceutical company that focuses on gastroenterology, oncology, neuroscience, and rare diseases. The company's stock is up more than 9% this year, currently trading at just shy of $15.
- Reuters
Grifols shares soar as plasma collection reaches pre-pandemic levels
Spanish pharmaceuticals company Grifols' shares soared on Friday as the company reported the volumes of blood plasma it collected reached pre-pandemic levels in the first quarter. Grifols' collection of the blood plasma it uses to make haematology medicines, collapsed during the COVID-19 pandemic when its collection centres around the world were closed, hitting its net profit, which fell 70% in 2021. As a result Grifols lost around 50% of its market value since the COVID-19 pandemic started in 2020 when its shares were trading at record levels.
- Reuters
Grifols' profit slides 70% on blood plasma supply disruption
BARCELONA (Reuters) -Spanish pharmaceuticals company Grifols' full-year net profit fell 70% to 183 million euros ($204.70 million) as the COVID-19 pandemic continued to disrupt supplies of the blood plasma it uses to make medicines. Grifols said the pandemic had a negative impact of 503 million euros on core earnings, mainly because of lower collection of blood plasma, which was down 4% year on year, though there was an improvement in the fourth quarter. The Barcelona-based company expects plasma collection to continue rising in 2022, which would reduce the blood's cost and increase Grifols' profitability, it said in a statement.
